TITLE

Hepatitis C Virus Genotype 1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American and White Patients

AUTHOR(S)
Layden-Almer, Jennifer E.; Kuiken, Carla; Ribeiro, Ruy M.; Kunstman, Kevin J.; Perelson, Alan S.; Layden, Thomas J.; Wolinsky, Steven M.
PUB. DATE
September 2005
SOURCE
Journal of Infectious Diseases;9/15/2005, Vol. 192 Issue 6, p1078
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In hepatitis C virus (HCV) infection, race is a determinant of treatment response and interferon (IFN) effectiveness. Here, we investigated whether there were differences in the pretreatment viral strains between African American patients and white patients and whether these differences correlated with viral kinetics. IFN effectiveness was calculated using a viral kinetic model. The HCV NS5A region from 21 treated patients with HCV genotype la was sequenced and analyzed. White patients displayed more mutations in the V3 region (mean ± SD, 4.5 ± 1.4 vs. 2.9 ± 1.6; p = .016), and treatment responders tended to have more mutations in this region than did nonresponders. There was a significant positive correlation between IFN effectiveness and the number of mutations in the V3 region (P = .03). There was no clustering of strains by race, treatment response, or IFN effectiveness in phylogenetic analyses. The results of this study, in conjunction with those of a previous study illustrating the impaired IFN effectiveness in African Americans, suggest a role for host-related factors.
ACCESSION #
17988620

 

Related Articles

  • Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. Chen-Hua Liu; Chun-Jen Liu; Chih-Lin Lin; Cheng-Chao Liang; Shih-Jer Hsu; Sheng-Shun Yang; Ching-Sheng Hsu; Tai-Chung Tseng; Chia-Chi Wang; Ming-Yang Lai; Jun-Herng Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1260 

    Background. Comparable sustained virologic response (SVR) rates have been documented between Asian patients who received 24 weeks of pegylated interferon (IFN) plus ribavirin and white patients who received 48 weeks of combination therapy for hepatitis C virus genotype 1 (HCV-1) infection....

  • Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. Donlin, Maureen J.; Cannon, Nathan A.; Aurora, Rajeev; Jia Li; Wahed, Abdus S.; Bisceglie, Adrian M. Di; Tavis, John E. // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: Hepatitis C virus (HCV) has six major genotypes, and patients infected with genotype 1 respond less well to interferon-based therapy than other genotypes. African American patients respond to interferon α-based therapy at about half the rate of Caucasian Americans. The effect of...

  • Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Alsiö, Åsa; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L.; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, pe22 

    Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load....

  • Clinical Significance of In Vitro Replication-- Enhancing Mutations of the Hepatitis C Virus (H CV) Replicon in Patients with Chronic HCV Infection. Sarrazin, Christoph; Mihm, Ulrike; Herrmann, Eva; Welsch, Christoph; Albrecht, Mario; Sarrazin, Ulrike; Traver, Stella; Lengauer, Thomas; Zeuzem, Stefan // Journal of Infectious Diseases;11/15/2005, Vol. 192 Issue 10, p1710 

    Background. Mutations in nonstructural (NS) hepatitis C virus (H CV) proteins enhance replication in HCV-1 a/b replicons. The prevalence of such mutations and their clinical significance in vivo are unknown. Methods. Parts of HCV NS3 and NS4B-NS5B genes that included 31 in vitro...

  • Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Rocco, Alba; Compare, Debora; Coccoli, Pietro; Esposito, Ciro; Spirito, Antimo Di; Barbato, Antonio; Strazzullo, Pasquale; Nardone, Gerardo // Gut;May2013, Vol. 62 Issue 5, p766 

    Background In vitro, vitamin B12 acts as a natural inhibitor of hepatitis C virus (HCV) replication. Objective To assess the effect of vitamin B12 on virological response in patients with chronic HCV hepatitis naïve to antiviral therapy. Methods Ninety-four patients with chronic HCV hepatitis...

  • Providing treatment for hepatitis C in an Australian district centre. Ewart A; Harrison L; Joyner B; Safe A // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p180 

    Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and...

  • Providing treatment for hepatitis C in an Australian district centre. Ewart A; Harrison L; Joyner B; Safe A // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p180 

    Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and...

  • Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a 46-year-old Japanese woman, who was donating her liver to her brother, who had decompensated liver cirrhosis of unknown origin. It mentions that she had a mild liver dysfunction which was diagnosed as a hepatitis C virus (HCV) infection (serotype 2), eight...

  • Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines. Ali, Liaqat; Idrees, Muhammad; Ali, Muhammad; Hussain, Abrar; Rehman, Irshad Ur; Ali, Amjad; Iqbal, Syed Abbas; Kamel, Eyad Hassan // BMC Research Notes;2014, Vol. 7 Issue 1, p2 

    Background Hepatitis C virus (HCV) is estimated to infect 200 million individuals in the globe, including approximately 10 million in Pakistan causing both acute and chronic hepatitis. The standard treatment against HCV is pegylated interferon therapy in combination with a nucleoside analogue...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics